THIS WEBSITE HAS BEEN PRODUCED BY SHIRE AND IS NOT INTENDED FOR RESIDENTS OF THE USA, IRELAND AND THE UK
* After 24 months of Replagal, the probability of a first composite cardiac, cerebrovascular or renal morbidity event was approximately 16% in the overall population and approximately 26% for males only. In the untreated population, the probability of a first composite event was approximately 45%.
1. Beck M. et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015;3:21–27.
This website is intended to provide information to a healthcare professional audience outside the USA, Ireland and UK. It contains information on Replagal, based on the Summary of Product Characteristics as approved by the European Medicines Agency.
This website is not intended to be used to report adverse events or product quality complaints. If you would like to report an adverse event or product quality complaint, please contact email@example.com.
For more information on Replagal, please click here.
Job code: C-APROM/INT//0390 | Date of preparation: August 2017